Monopar Therapeutics Launches Phase 1a uPAR-Targeted Cancer Trial

Monopar Therapeutics Inc ( (MNPR) ) has provided an update.

Monopar Therapeutics Inc. is advancing the fight against cancer with the initiation of a Phase 1a clinical trial for its innovative radiopharmaceutical therapy, MNPR-101-Lu, targeting advanced cancers. The therapy is designed to selectively attack cancer cells by focusing on the urokinase plasminogen activator receptor (uPAR), common in various tumor types. With promising clinical and preclinical data, Monopar is optimistic about this potential first-in-the-world uPAR-targeted treatment, aiming to improve outcomes with minimal harm to healthy tissue.

For an in-depth examination of MNPR stock, go to TipRanks’ Stock Analysis page.